ORPHA:91138
Cryoglobulinemic vasculitis
Also known as: Essential cryoglobulinemia · Essential mixed cryoglobulinemia · Mixed cryoglobulinemia · Primary cryoglobulinemia
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
6,627
Trials
5
Interventional, condition-specific
Researchers
1,242
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare immune complex-mediated vasculitis characterized by the presence of circulating cryoprecipitable immune complexes in the serum, manifesting clinically with the classical triad of purpura, weakness and arthralgia.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007407
- MeSH:C565141
- OMIM:123550
- UMLS:C1852456
Additional Mondo synonyms (6)
MC · Mixed Cryoglobulinemia · essential cryoglobulinemia · essential mixed cryoglobulinemia · mixed cryoglobulinemia · primary cryoglobulinemia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
6,627 matched papers (2,484 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
5 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
6,627
6,627 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
6,627 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
2,484 in the last 10 years · low confidence
Phrase hits: 6,627 · MeSH hits: 0
Who's working on it?
1,242
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Gragnani L9 papers · 2026
MASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Papers in Europe PMC - 02Quartuccio L9 papers · 2026
Rheumatology Clinic Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy.
Papers in Europe PMC - 03Zignego AL9 papers · 2026
MASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy - annalinda.zignego@unifi.it.
Papers in Europe PMC - 04Visentini M8 papers · 2026
Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Papers in Europe PMC - 05Casato M6 papers · 2026
Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Papers in Europe PMC - 06Ferri C6 papers · 2026
Rheumatology Clinic 'Madonna dello Scoglio' Cotronei, Crotone, Italy. clferri@unimore.it.
Papers in Europe PMC - 07Lauletta G6 papers · 2026
Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy.
Papers in Europe PMC - 08Mazzaro C6 papers · 2026
Clinical Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Papers in Europe PMC - 09Treppo E6 papers · 2026
Rheumatology Clinic Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy.
Papers in Europe PMC - 10Vacchi C6 papers · 2026
Rheumatology Unit, Azienda Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
5
interventional trials for this specific condition
5 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 190 trials are registered for vasculitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
5 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 87.9th percentile).
low confidence · 87.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
5 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07268521·NOT YET RECRUITING·A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab
Conditions: Cryoglobulinemic Vasculitis (CV)·Matched via name phrase
Broader category: vasculitis
190
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07388277·RECRUITING·CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis·Matched via name phrase
- NCT06277427·RECRUITING·Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Conditions: Lupus Nephritis · ANCA Associated Vasculitis·Matched via name phrase
- NCT07448454·NOT YET RECRUITING·Role of Vessel Wall MRI in Differentiaition Between Intracranial Atherosclerotic Disease and Vasculitis as Causes of Ischemic Stroke
Conditions: Intracranial Atherosclerotic Disease (ICAD) and Vasculitis·Matched via name phrase
- NCT07315087·RECRUITING·CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Conditions: SLE - Systemic Lupus Erythematosus · SSc-Systemic Sclerosis · IIM- Idiopathic Inflammatory Myopathies · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06986018·NOT YET RECRUITING·Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
Conditions: Idiopathic Inflammatory Myopathies · ANCA-Associated Vasculitis·Matched via name phrase
- NCT06980597·RECRUITING·A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Idiopathic Inflammatory Myopathy (IIM) · Systemic Sclerosis (SSc) · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06821659·NOT YET RECRUITING·Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erthematosus · Systemic Sclerosis (SSc) · Inflammatory Myopathies · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06868290·RECRUITING·Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Conditions: ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06335888·RECRUITING·A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
Conditions: Giant Cell Arteritis·Matched via name phrase
- NCT07246096·RECRUITING·Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Conditions: Autoimmune Diseases · Systemic Lupus Erythematosus · Systemic Sclerosis · Primary Sjögren Syndrome·Matched via name phrase
- NCT06611696·RECRUITING·Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Conditions: ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT07339540·RECRUITING·the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Conditions: Recurrent or Refractory Systemic Lupus Erythematosus · Recurrent or Refractory IgG4 Related Diseases · Recurrent or Refractory Systemic Sclerosis · Recurrent or Refractory Idiopathic Inflammatory Myopathy·Matched via name phrase
- NCT03290456·RECRUITING·Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
Conditions: Granulomatosis With Polyangitis·Matched via name phrase
- NCT07236801·RECRUITING·Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis · Sjogren's Syndrome (SS) · Inflammatory Myopathy·Matched via name phrase
- NCT06828042·RECRUITING·Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erthematosus · Systemic Sclerosis (SSc) · Sjogren Syndrome · ANCA Associated Vasculitis (AAV)·Matched via name phrase
Observational and natural-history studies
6 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03004326·RECRUITING·Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Conditions: Cryoglobulinemic Vasculitis (CV) · Drug-induced Vasculitis · Eosinophilic Granulomatosis With Polyangiitis (EGPA) · IgA Vasculitis·Matched via name phrase
- NCT02593565·RECRUITING·Vasculitis Pregnancy Registry
Conditions: Vasculitis · Behcet's Disease · CNS Vasculitis · Cryoglobulinemic Vasculitis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Cryoglobulinemic vasculitis" OR "Essential cryoglobulinemia" OR "Essential mixed cryoglobulinemia" OR "Mixed cryoglobulinemia" OR "Primary cryoglobulinemia"
MeSH descriptor terms unioned into the query: Cryoglobulinemia, Familial Mixed
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Cryoglobulinemic vasculitis" OR "Essential cryoglobulinemia" OR "Essential mixed cryoglobulinemia" OR "Mixed cryoglobulinemia" OR "Primary cryoglobulinemia" OR "Cryoglobulinemia, Familial Mixed"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 5 interventional · 6 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"vasculitis"
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (6627) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T03:57:42.641Z
